{"id":"W4386755083","doi":"10.33590/emj/10308910","title":"Improving the Effectiveness of Anticoagulant Therapy: The Promise of Factor XI Inhibition","year":2023,"lang":"en","type":"article","venue":"European Medical Journal","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Esperion Therapeutics; HLS Therapeutics; Servier; Duke Clinical Research Institute; Novo Nordisk; Regeneron Pharmaceuticals; York University; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Idorsia Pharmaceuticals; University of Toronto; Cleveland Clinic; Alnylam Pharmaceuticals; Pfizer; Heart and Stroke Foundation of Canada; Daiichi Sankyo Europe; American Regent; Sanofi; Amgen","keywords":"Medicine; Intensive care medicine; Rivaroxaban; Population; Warfarin; Discovery and development of direct thrombin inhibitors; Regimen; Anticoagulant; Atrial fibrillation; Apixaban; Clinical trial; Thrombosis; Major bleeding; Internal medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004175209,0.0001169039,0.0002652929,0.00008203788,0.0001580986,0.00002114915,0.0001876736,0.00004141456,0.0001908623],"category_scores_gemma":[0.00120114,0.00005385082,0.0001866093,0.0002916021,0.0002678855,0.00005467778,0.00007019866,0.0003799664,0.00002179172],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001685045,"about_ca_system_score_gemma":0.000183408,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001585918,"about_ca_topic_score_gemma":7.768185e-7,"domain_scores_codex":[0.9974349,0.0009605489,0.0004680604,0.0001238706,0.0008067596,0.0002058574],"domain_scores_gemma":[0.998517,0.0007047588,0.0002602435,0.0002159424,0.0001440403,0.0001580011],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.002391504,0.0006628613,0.1069958,0.0008118087,0.0006407263,0.0010997,0.005961702,0.00003460436,0.3863956,0.001181259,0.00307757,0.4907469],"study_design_scores_gemma":[0.002732842,0.0004092917,0.9588931,0.001034211,0.00006348148,0.0004948925,0.0002521664,0.0007358884,0.03411642,0.0001793674,0.0009998186,0.00008849578],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961733,0.0007006372,0.0005335209,0.001274727,0.0003154289,0.0003048127,0.000004491461,0.00003459723,0.000658439],"genre_scores_gemma":[0.9986351,0.000453406,0.00001839705,0.0002113036,0.0005645043,0.00000194667,0.000006739102,0.0000272888,0.00008127676],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8518974,"threshold_uncertainty_score":0.2195973,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02770444359575574,"score_gpt":0.2790438000973046,"score_spread":0.2513393565015489,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}